公司报告收入增长强, 并推进药物开发管道. Company reports strong revenue growth and advances drug development pipeline.

2026年第一季度财务报告显示收入增长强. Q1 2026 financial reports indicate strong revenue growth. 该公司还强调了其治疗管道的进步,表明药物开发计划取得进展. The company also highlighted the advancement of its therapeutics pipeline, signaling progress in its drug development initiatives.